Akums Drugs and Pharmaceuticals Limited share price
NSE: AKUMS · ISIN INE09XN01023
Key numbers
- Market cap
- ₹ 12,548 Cr
- Current price
- ₹ 819.55
- 52-week high / low
- ₹ 839 / 409
- Stock P/E
- 42.9
- Book value
- ₹ 216.4
- Dividend yield
- 0.12%
- ROCE
- 14.2%
- ROE
- 8.0%
- Debt to equity
- 0.06
- Sales growth (3 yrs)
- 7.0%
- Profit growth (3 yrs)
- 39.1%
- 1-year return
- 72.4%
About Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-seal products, topical preparations, eye drops, dry powder injections, and gummies for therapeutic areas, such as antiinfectives, pain management, gastroenterology, orthopaedics, cardio-diabetic care, critical care, respiratory, and gynaecology. In addition, the company operates as pharmaceutical contract development and manufacturing company. Akums Drugs and Pharmaceuticals Limited was incorporated in 2004 and is based in Delhi, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 1,024 | 1,018 | 1,160 | 1,158 | 1,167 |
| Operating profit | 129 | 94 | 147 | 152 | 175 |
| Net profit | 63 | 41 | 66 | 85 | 100 |
| EPS (₹) | 4.15 | 2.66 | 4.33 | 5.53 | 6.53 |
Concall summary (2026-08-13)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- Quarter 1 FY26, we were at 12.6%, and 187 basis points quarter-on-quarter or Q4 FY26, we were at 13.1%.
- If we were to look at the various segments and their performance, if we start with the CDMO, the revenue stood at INR964 crores, increase of 18.6% year-on-year, we were at INR813 crores Q1 FY26, an increase of 1.3% quarter-on-quarter, Q4 FY26, we were at INR952 crores.
Growth & demand
- CDMO once again delivered a healthy top- line growth of over 18%, aided by both volume growth and improvement in API prices.
- Akumentis, our domestic branded formulations segment, restarted its growth journey with a healthy 7% revenue growth during the quarter.
Margins & costs
- We registered a healthy revenue growth of over 13% with EBITDA increasing by more than 30%.
- EBITDA margins stood at 17.1%, increasing 231 basis points Year-on-year, Q1 FY26, we were at 14.8% and quarter-on-quarter Q4 '26, we were at 15.7%.
Capex & expansion
- And as far as the capacity utilization strategy is concerned, you've always invested in a lot of capacity and you believe in having a lot of spare capacity.
- Sir, on the last participant, you said the capacity utilization was already around 50%, and we can maximum go up to 55%.
Balance sheet & cash
- The operating cash flow for the company for the quarter 1 stood at INR65 crores.
- So our net worth sits at more than INR3,400 crores and there is no debt on the company.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.